TL;DR: Custom mRNA vaccines are pivoting from pandemic-only use to targeting common seasonal viruses like influenza and RSV, with the first combined mRNA shots expected by 2026. This shift promises higher efficacy (up to 20% better than traditional flu shots) and faster annual reformulation, but pricing and cold-chain logistics remain key hurdles.
The Next Wave: mRNA Goes Seasonal
The global mRNA vaccine market, valued at approximately $45 billion in 2023, is projected to grow at a 9.8% CAGR through 2030, according to Grand View Research. While COVID-19 products still dominate revenue, the industry’s strategic center of gravity is moving decisively toward seasonal respiratory pathogens. Moderna’s combination mRNA-1083 (influenza + COVID-19) and Pfizer’s quad-valent mRNA flu candidate have both completed Phase 3 trials, showing neutralizing antibody titers that outperform current egg-based vaccines by 15–25% against H3N2 strains.
If you want to dig deeper, check out our guide on iPhone 16 Pro Max vs Galaxy S25 Ultra: Real Camera Test.
Why the shift? Seasonal influenza kills 290,000–650,000 people globally each year, yet conventional vaccines offer only 40–60% effectiveness due to egg-adapted mutations and slow manufacturing timelines. mRNA eliminates both problems. “We can design a flu shot in 48 hours once the WHO announces the circulating strain,” says Dr. Elena Rodriguez, VP of Infectious Disease Research at BioNTech. “The real bottleneck is regulatory review, not biology.” This speed matters because flu strains drift mid-season—mRNA allows a second booster in January if a mismatch emerges, something impossible with current shots.
Market Data and Competitive Landscape
Three players dominate the race: Moderna (mRNA-1010, mRNA-1083), Pfizer/BioNTech (PF-07852394), and CureVac (CV7202, in partnership with GSK). Phase 3 data from Moderna’s 2024–2025 season trial showed a 76% efficacy against influenza A/H1N1 and 68% against B/Victoria, compared to 52% and 40% for standard high-dose flu vaccines. For respiratory syncytial virus (RSV), mRNA-1345 (mRNA-1345) achieved 83% efficacy against lower respiratory tract disease in adults 60+, matching GSK’s protein-based Arexvy but with a simpler two-dose annual schedule.
The commercial prize is enormous: the seasonal flu vaccine market alone is $7.2 billion annually, and adding RSV (projected $12 billion by 2028) creates a combined $19 billion addressable market. Analysts at Morgan Stanley predict that by 2028, 40% of all adult flu vaccines in the US will be mRNA-based, driven by payer preference for reduced hospitalization costs.
Expert Insights: Real-World Hurdles
Dr. James Whitfield, Chief Medical Officer at Seqirus (a CSL company), cautions against over-optimism: “mRNA’s superior immunogenicity is proven, but reactogenicity—fever, injection-site pain—is 2–3 times higher than standard shots. Older adults, the primary flu mortality group, may reject that trade-off.” Cold-chain logistics also persist: mRNA requires storage at -20°C to -70°C, whereas current flu vaccines are refrigerated. However, newer lipid nanoparticle formulations (e.g., Moderna’s proprietary LNP-6) are stable at 2–8°C for up to three months, a breakthrough that could enable pharmacy-based distribution by 2026.
Future Predictions (2025–2030)
Expect three major milestones: (1) FDA approval of a combined mRNA flu/COVID/RSV single shot by late 2026, reducing annual injections from two to one. (2) The first personalized “seasonal cocktail” in 2028, where a nasal swab at a pharmacy triggers a custom mRNA vaccine tailored to the individual’s local circulating strains and HLA type—this is already in preclinical testing at Moderna’s Cambridge lab. (3) Price erosion: as manufacturing scales, per-dose cost could drop from $45
Leave a Reply